New partnership to bring increased efficiency and patient centricity in trial execution.
Worldwide Clinical Trials, Inc. (Worldwide) and Science 37 Holdings, Inc. today announced a collaboration to enable decentralized clinical trial delivery in which patient visits for the provision of healthcare or trial assessments and laboratory tests are localized in the patient’s community. With this new partnership, Worldwide will leverage Science 37’s Operating System.
Through this partnership, Worldwide Clinical Trials becomes part of the Science 37 CRO Certified network.
Read more about the new partnership here.
Phase III Trial of Keytruda Plus Lynparza for NSCLC Stopped Due to Futility
December 7th 2023KEYLYNK-008 trial finds that Keytruda in combination with chemotherapy followed by Keytruda plus Lynparza did not produce an improved overall survival benefit in patients with metastatic squamous non-small cell lung cancer.
Key Phase III Trial Results Lead to FDA Approval of Fabhalta for Paroxysmal Nocturnal Hemoglobinuria
December 6th 2023Clinical trials demonstrated superiority of Fabhalta to anti-C5s in hemoglobin improvement in the absence of transfusions and transfusion avoidance rate, showing clinically meaningful hemoglobin-level increases without the need for blood transfusions in patients with paroxysmal nocturnal hemoglobinuria.